Table 3.
Patients' Demographic and Clinical Data
| |
rs13281615 |
|
|
|||
|---|---|---|---|---|---|---|
| AA | AG | GG | AG+GG | pa | pb | |
| N | 100 | 215 | 102 | 317 | ||
| Age, year | 49.1±10.9 | 49.0±9.7 | 50.3±10.6 | 49.4±10.0 | 0.526 | 0.764 |
| Weight, kg | 62.2±9.7 | 61.9±9.0 | 64.5±10.3 | 62.7±9.5 | 0.060 | 0.590 |
| Height, cm | 160.7±4.6 | 160.1±4.5 | 161.3±4.6 | 160.5±4.6 | 0.070 | 0.666 |
| BMI, kg/m2 | 24.0±3.4 | 24.2±3.4 | 24.8±3.4 | 24.4±3.4 | 0.253 | 0.418 |
| Initial lidocaine, mg | 66.5 [66.5,66.5] | 66.5 [66.5,66.5] | 66.5 [66.5,66.5] | 66.5 [66.5,66.5] | 0.806 | 0.584 |
| Total ropivacaine, mg | 50.8 [38.1,67.9] | 52.6 [40.6,67.8] | 61.4 [50.0,75.7] | 54.5 [42.0,71.5] | 0.001 | 0.047 |
| Onset of ropivacaine, min | 6.0 [5.0,7.0] | 6.0 [5.0,7.0] | 6.0 [5.0,8.0] | 6.0 [5.0,7.0] | 0.103 | 0.055 |
| Duration of surgery, min | 100.0 [75.0,120.0] | 90.0 [75.0,120.0] | 105.0 [80.0,120.0] | 90.0 [75.0,120.0] | 0.163 | 0.573 |
| Mean ropivacaine, mg/min | 0.5 [0.4,0.7] | 0.6 [0.4,0.8] | 0.6 [0.5,0.8] | 0.6 [0.5,0.8] | 0.003 | 0.003 |
Data are expressed as numbers, mean±SD or median [interquartile range].
a
p-Value comparing the three genotype groups separately.
b
p-Value in a dominant model, comparing the group of homozygotes for the nonrisk allele with the combined group of heterozygotes and homozygotes for the risk allele.
BMI, body mass index.